Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for treating coronary atherosclerosis and preparation method of medicine

A coronary atherosclerosis and drug technology, applied in the medical field, can solve the problems of drug resistance, side effects, and chronic stenosis in patients, and achieve the effects of reducing myocardial oxygen consumption, increasing normal heart contraction, and good curative effect

Inactive Publication Date: 2019-01-08
陈新忠
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Common drugs for the treatment of coronary atherosclerosis include: nitrates, β-receptor blockers, etc. These drugs are likely to cause drug resistance in patients and have side effects; surgical treatment is mainly stents, bypasses, but there are It may be chronic stenosis again, which will not only cause chest tightness and chest pain, but also may require another operation, which is expensive and cannot be done once and for all.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for treating coronary atherosclerosis and preparation method of medicine
  • Medicine for treating coronary atherosclerosis and preparation method of medicine
  • Medicine for treating coronary atherosclerosis and preparation method of medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] A medicament for treating coronary atherosclerosis according to Example 1 of the present invention is made of the following raw materials in weight ratio:

[0039] 10 parts of peach kernel, 20 parts of heterophylla, 20 parts of astragalus, 10 parts of cassia twig, 20 parts of salvianolic acid B, 10 parts of ligustrazine hydrochloride, and 10 parts of meglumine cyclophosphate.

[0040] The preparation method of a kind of medicine for the treatment of coronary atherosclerosis of present embodiment 1:

[0041] Step 1: Send peach kernels, Radix Pseudostellariae Pseudostellariae, Radix Astragali, Cinnamon Twig, Salvianolic Acid B, Ligustrazine Hydrochloride, and Glumine Cyclic Acid into the first disperser, disperse and rotate at a speed of 600r / min for 1 hour, Obtain the mixture; step 2, send the mixture of step 1 into the first sand mill for grinding, the temperature in the sand mill is 45°C, and obtain a powder with a fineness of 7.5 microns; step 3, the powder in step 2 ...

Embodiment 2

[0043] A medicine for treating coronary atherosclerosis according to Example 2 of the present invention is made of the following raw materials in weight ratio: 25 parts of peach kernels, 35 parts of heterophylla, 35 parts of astragalus, 14 parts of cassia twig, and 35 parts of salvianolic acid B , 15 parts of ligustrazine hydrochloride, 20 parts of meglumine cyclic adenosine monophosphate.

[0044]The preparation method of a kind of medicine for treating coronary atherosclerosis of present embodiment 2, step 1, the walnut kernel, Radix Pseudostellariae, Radix Astragali, Cinnamon Twig, salvianolic acid B, ligustrazine hydrochloride, cyclic adenosine monophosphate glucose The amine is sent into the first disperser, and dispersed and rotated at a speed of 900r / min for 2 hours to obtain a mixture; in step 2, the mixture in step 1 is sent to the first sand mill for grinding, and the temperature in the sand mill is 55°C to obtain a fine A powder with a fineness of 7 microns; step 3,...

Embodiment 3

[0046] A medicine for treating coronary atherosclerosis according to Example 3 of the present invention is made of the following raw materials in weight ratio: 17 parts of peach kernels, 26 parts of Radix Pseudostellariae, 26 parts of Radix Astragali, 11 parts of Guizhi, and 26 parts of salvianolic acid B , 13 parts of ligustrazine hydrochloride, 16 parts of meglumine cyclic adenosine monophosphate.

[0047] The preparation method of a kind of medicine for treating coronary atherosclerosis of present embodiment 3, step 1, the walnut kernel, Radix Pseudostellariae, Radix Astragali, Cinnamon Twig, salvianolic acid B, ligustrazine hydrochloride, cyclic adenosine monophosphate glucose Send the amine into the first disperser, disperse and rotate at a speed of 800r / min for 1-2h, and obtain the mixture; step 2, send the mixture of step 1 into the first sand mill for grinding, and the temperature inside the sand mill is 50°C. Obtain a powder with a fineness of 6 microns; step 3, send ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicine for treating coronary atherosclerosis and a preparation method of the medicine. The medicine is prepared from the following raw materials in parts by weight: 10-30parts of semen persicae, 20-40 parts of radix pseudostellariae, 20-40 parts of astragalus mongholicus, 10-14 parts of ramulus cinnamomi, 20-40 parts of danshinolic acid B, 10-20 parts of ligustrazinehydrochloride and 10-20 parts of meglumine adenosine cyclophosphate. According to the medicine for treating the coronary atherosclerosis and the preparation method of the medicine, the medicine is processed by an advanced formula; the semen persicae, the radix pseudostellariae, the astragalus mongholicus and the ramulus cinnamomi have effects of reducing blood pressure, removing fever, increasinga coronary blood flow and distending blood vessels, and can distend coronary arteries and peripheral blood vessels and the like of a whole body, enhance normal systole and reduce myocardial oxygen consumption; and danshinolic acid B, ligustrazine hydrochloride and meglumine adenosine cyclophosphate are applicable to occlusive vascular diseases, thrombosis, vasculitis, coronary heart diseases, angina and the like and have a better treatment effect on an acute stage, a recovery phase and sequelae (such as thrombosis, embolism and arteriosclerosis) of ischemic vascular diseases.

Description

technical field [0001] The invention relates to the field of medical technology, in particular to a medicine for treating coronary atherosclerosis and a preparation method thereof. Background technique [0002] Coronary atherosclerotic heart disease, referred to as coronary heart disease, refers to myocardial dysfunction and (or) organic disease caused by coronary artery stenosis and insufficient blood supply. At present, coronary heart disease has become the "number one killer" that threatens the life and health of Chinese urban and rural residents. Moreover, with the acceleration of aging and urbanization, problems such as reduced physical activity and unreasonable diet structure are becoming more and more serious. At present, there are as many as 60 million patients with coronary heart disease in my country. And with the continuous improvement of material living standards, its incidence rate is also increasing. It is not only a common disease of the elderly, but also gra...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/736A61P9/10A61K31/343A61K31/4965A61K31/7076
CPCA61K31/343A61K31/4965A61K31/7076A61K36/36A61K36/481A61K36/54A61K36/736A61P9/10A61K2300/00
Inventor 陈新忠朱宏飞
Owner 陈新忠
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products